As the biologics landscape diversifies beyond monoclonal antibodies and traditional expression systems, there is increasing demand for alternative microbial hosts that combine scalability, safety, and process efficiency. While Escherichia coli and CHO cells dominate much of the contract development and manufacturing ecosystem, Bacillus—particularly Bacillus subtilis, Bacillus licheniformis, and Bacillus megaterium—has re-emerged as a strategic microbial […]